Associate Director

Karen Woodward, Ed.M., is a lung cancer advocate who came to the work through personal experience with cancer. She joined MET Crusaders as Volunteer Associate Director in 2025, where she helps strengthen the organization so people with MET-altered cancers have the information they need to make informed decisions and find a supportive community. She brings more than twenty years of nonprofit strategy consulting experience to her role, with a focus on building connections across the lung cancer advocacy and research communities. She is a participant in LUNGevity’s Citizen Scientist Program, a member of IASLC’s STARS Patient Research Advocate program, and a Research Advocate Grant Reviewer for the Lung Cancer Research Foundation. She is also active with LungCAN, GO2, ASCO, and A Breath of Hope Lung Cancer Foundation. She lives in the greater Minneapolis–St. Paul area.

Senior Patient Advocate
Chair, Speaker’s Bureau

Maggie McCloskey is a lung cancer patient and survivor who has channeled her personal experience into active advocacy in the research and clinical communities. Since 2022, she has served as a patient reviewer for research grant funding, including with the Lung Cancer Research Foundation, and has participated in expert patient panels on clinical trial access and physician-patient communication. Her recent work includes contributing to a continuing medical education course on MET alterations for PeerView, serving on patient advisory panels for BioNTech and Johnson & Johnson at ASCO 2025, and contributing to patient education videos for Caris Life Sciences and The Patient Story. She is a member of IASLC, ASCO, and AACR, with a particular focus on resistance to targeted therapies. At MET Crusaders, she serves as Chair of the Speaker’s Bureau.

Honorary Chair

Ravi Salgia, MD, PhD, is the Arthur & Rosalie Kaplan Chair in Medical Oncology at City of Hope’s comprehensive cancer center. There, he leads over 100 medical oncology faculty as professor and chair of the Department of Medical Oncology & Therapeutics Research.

Prior to joining City of Hope, Dr. Salgia served as a tenured professor of medicine, pathology, and dermatology, director of the Thoracic Oncology Program and the Aerodigestive Tract Program Translational Research Lab in the section of hematology/oncology, vice chair for translational research in the Department of Medicine, and associate director for translational science at the University of Chicago Comprehensive Cancer Center in Chicago. Prior to the University of Chicago, he was a faculty member at the Dana-Farber Institute and Harvard Medical School for a decade, initially as an instructor of medicine, then assistant professor of medicine.

Dr. Salgia earned his undergraduate summa cum laude in mathematics, biology, and chemistry, and then his medical doctorate and Ph.D. from Loyola University in Chicago, where he also completed fellowships in neurochemistry and physiology. As an undergraduate and graduate student, he published several manuscripts in mathematics and basic sciences. He continued his postgraduate training with an internship and residency in internal medicine at The Johns Hopkins Hospital in Baltimore, followed by a fellowship in medical oncology at the Dana-Farber Cancer Institute in Boston, during which he also served as a clinical fellow at Harvard Medical School.

Board-certified in medical oncology, Dr. Salgia serves on various panels for the National Cancer Institute. He has consistently received research grants from the National Institutes of Health and has been awarded several inventions, discoveries, and patents related to his research. He is the co-chief editor of the Journal of Carcinogenesis. Dr. Salgia also serves on the editorial advisory board of four additional journals. He has authored over 550 peer-reviewed articles, reviews, and editorials, three books, and over 30 book chapters.

Dr. Salgia is frequently invited to present his work at national and international conferences and symposia, and is the recipient of several honors and awards, including πμε National Competition in Mathematics, Richard V. Andree Award for “Volume of an n-Dimensional Unit Sphere,” 2016 Asclepius Award from the Bonnie J. Addario Lung Cancer Foundation, IACA Award for Outstanding Contributions to Oncology, Sun Pharma Award and served as a member of NIH/NCI’s Tumor Progression and Metastasis Study Section, and CONC Study Section. He is currently on the board of directors for the National Comprehensive Cancer Network. He is part of the CI4CC “Directors Circle.” He is on the local leadership board for the American Lung Association. Also, he is recognized on “Best Doctors” and “Top Doctors” lists, and is listed in Wikipedia.

Dr. Salgia’s bio courtesy of City of Hope.

Bio coming soon…

Patient Advocate
Chair, Welcome Committee

Amy Grove was diagnosed with Stage IV Squamous Non-Small Cell Lung Cancer in 2018 and has since built a career in patient advocacy and lung cancer education. She administers four major lung cancer support groups with thousands of members, providing patients and care partners with trusted information, resources, and community. A vocal proponent of biomarker testing — including in squamous cell cases where it is often overlooked — she shares her own experience of discovering a MET amplification and achieving six years of stability on targeted therapy. She stays current with oncology research through ASCO, AACR, GO2 Foundation Advocacy Day, and LUNGevity’s HOPE Summits. Her story has been featured in Patient Resource, The Patient Story, and the podcast Pivoting: Personal Stories of Transformation. At MET Crusaders, she serves as Chair of the Welcome Committee.

Senior Patient Advocate

Susan joined the Exon 20 Group at ICAN after caring for her late husband throughout his cancer journey. Following a 33-year career with the United States Postal Service, Susan now honors her husband’s legacy by supporting others facing similar challenges. As a patient advocate for  ICAN’s biomarker support group, the MET Crusaders, she offers compassionate guidance to individuals and families at every stage of treatment, helping them navigate complex medical systems and connect with essential resources. Susan lives in Orange County, California, and cherishes time with her grandchildren. For her, everyday is a gift and one that should be celebrated and shared with those they love. Finding joy in all things is a task that she takes seriously.

Chief, Oncology Nursing Services

Carmi Fazio, RN MSN ONS, is a registered nurse currently living and working in Niles, Illinois. Her areas of expertise are in oncology and end of life nursing. As an RN, she has worked in oncology since 2006. She received her Associate degree in 2005, her Bachelor’s degree in 2012 and a Masters in Nursing Education in 2016. She graduated as a member of the prestigious Golden Key International Honor Society.

Carmi has received many accolades for her work in oncology including Cure Magazine’s Extraordinary Healer Award in 2016, OptumCare/United Health Group (UHG) Superhero Award in 2018, a 2018 worldwide leader in healthcare from the International Nursing Association, and the Diamond Award for top professional in oncology nursing for outstanding achievements as a nurse and a cancer care specialist in 2018. She has completed interviews for the Oncology Nursing Society on a variety of oncology issues. She has appeared in CURE Magazine and Fra Noi (an Italian publication) for her achievements in oncology nursing. As Chair of the Oncology Nursing Council at ICAN, she co-authored a presentation for the 46th Annual Congress of Oncology in 2021 titled “Improving Patient Understanding of Testing in Precision Medicine with Consistent, Plain Language Testing Terms.”

Carmi works with patients at ICAN who seek counseling for symptom management, side effects, and pain management. When she isn’t working, Carmi likes to read and spend time with her siblings, mom, dogs, and friends.

Chair, MET Crusaders
President and CEO, ICAN, International Cancer Advocacy Network

Marcia Horn is President and CEO of ICAN, the International Cancer Advocacy Network, and Chair of MET Crusaders. At the MET Crusaders, the top priority is supporting MET patients and care partners throughout their journeys. As a global, pan-tumor, multi-stakeholder biomarker group, the MET Crusaders aims to make MET-altered cancers manageable—and ultimately curable. Our MET Research Consortium, in development, will help advance that mission by accelerating innovative MET research.

Marcia is entering her 30th year as a patient navigator with ICAN. At ICAN, she has directly navigated many thousands of pan-tumor patient cases in the U.S. and in 93 countries since the founding of the organization in 1996. She is a molecular profiling advocate, a clinical trials matching advocate, an expanded access/compassionate use advocate, and a global access advocate. The pan-tumor Exon 20 Group (for EGFR exon 20 and HER2 exon 20 insertion mutated cancer patients), the NRG1 Energizers (for NRG1 fusion positive cancer patients), the PD-L1 Amplifieds (for CD 274 positive cancer patients), and the Biomarker Collaborative, are also under ICAN’s umbrella.

In 2012, Marcia became DIA’s inaugural chair of its Patient Engagement Community and in 2013 was named one of the first PCORI Ambassadors. In her role as a research advocate, Marcia served, from 2014 to 2022, as one of the two research advocates for the Stand Up 2 Cancer Molecular Early Detection of Colon Cancer Dream Team, and the Stand Up 2 Cancer InTIME Dream Team for Lung Cancer Interception. Since 2018, she has served as a research advocate for the National Cancer Institute’s University of Texas Southwestern/MD Anderson Cancer Center Lung SPORE (Specialized Program of Research Excellence) working with John Minna, MD, and John Heymach, MD, PhD.

Having served for eight years as member of the ASCO TAPUR Study Molecular Tumor Board, Marcia was invited to serve on the ASCO TAPUR Steering Group. She worked with Razelle Kurzrock, MD, chair of SWOG’s Early Therapeutics/Rare Cancers Committee, as the committee’s research advocate. Marcia is currently serving as the advocate for the IASLC’s Rare Tumors Committee and is the patient advocate for the NCI’s Investigational Drugs Steering Committee. She recently concluded 14 years as a member of the Banner Health Institutional Review Board.

In spring of 2026, she was invited by Roy Herbst, MD, PhD, and Katerina Politi, PhD, onto the External Advisory Board for the Yale SPORE in Lung Cancer. She accepted the invitation of City of Hope’s Ravi Salgia, MD, PhD, to join the Advisory Board for their ARPA-H award which includes the IMMUNO-BIOMAP clinical trial which tracks tumor evolution during immunotherapy and assigns patients to biomarker-matched sub-trials targeting their resistance mechanism.

Marcia is a Phi Beta Kappa graduate of Stanford University in Political Science and received her JD from the Stanford Law School. Before joining ICAN, she practiced litigation and appellate law in Phoenix and held major leadership positions in the Arizona arts and civic community. Her son Yoni practices corporate law in California.